• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.

作者信息

Karran Eric, Hardy John

机构信息

Alzheimer's Research UK, Cambridge; Reta Lila Weston Laboratories, London; Department of Molecular Neuroscience, University College London, London, United Kingdom.

出版信息

Ann Neurol. 2014 Aug;76(2):185-205. doi: 10.1002/ana.24188. Epub 2014 Jul 2.

DOI:10.1002/ana.24188
PMID:24853080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4204160/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c58/4305203/3c2a81c5d7bc/ana0076-0185-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c58/4305203/c0b020668890/ana0076-0185-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c58/4305203/26e9f8b5255e/ana0076-0185-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c58/4305203/3c2a81c5d7bc/ana0076-0185-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c58/4305203/c0b020668890/ana0076-0185-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c58/4305203/26e9f8b5255e/ana0076-0185-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c58/4305203/3c2a81c5d7bc/ana0076-0185-f3.jpg

相似文献

1
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.对针对阿尔茨海默病淀粉样蛋白假说的药物发现及3期临床项目的批判。
Ann Neurol. 2014 Aug;76(2):185-205. doi: 10.1002/ana.24188. Epub 2014 Jul 2.
2
Failure analysis of clinical trials to test the amyloid hypothesis.用于检验淀粉样蛋白假说的临床试验的失败分析。
Ann Neurol. 2014 Aug;76(2):159-61. doi: 10.1002/ana.24227. Epub 2014 Jul 22.
3
Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?阿尔茨海默病淀粉样蛋白假说正处于十字路口：我们从何处出发？
Expert Opin Ther Targets. 2010 Dec;14(12):1273-7. doi: 10.1517/14728222.2010.528285.
4
Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease.致力于开发针对阿尔茨海默病淀粉样蛋白和tau蛋白病变的药物。
Int J Geriatr Psychiatry. 2011 May;26(5):546-8. doi: 10.1002/gps.2543.
5
CAN BIOGEN BEAT THE MEMORY THIEF?百健公司能战胜记忆窃贼吗？
Fortune. 2015 May 1;171(6):78-84, 86.
6
Tarenflurbil: a shot on goal.
Lancet Neurol. 2008 Jun;7(6):468-9. doi: 10.1016/S1474-4422(08)70091-7. Epub 2008 Apr 29.
7
Landmark Alzheimer's drug approval confounds research community.具有里程碑意义的阿尔茨海默病药物获批令研究界感到困惑。
Nature. 2021 Jun;594(7863):309-310. doi: 10.1038/d41586-021-01546-2.
8
Amyloid plaques are still main target for Alzheimer's drugs.淀粉样斑块仍然是治疗阿尔茨海默病药物的主要靶点。
BMJ. 2016 Jan 13;352:i214. doi: 10.1136/bmj.i214.
9
Solanezumab and the amyloid hypothesis for Alzheimer's disease.索拉珠单抗与阿尔茨海默病的淀粉样蛋白假说
BMJ. 2016 Dec 29;355:i6771. doi: 10.1136/bmj.i6771.
10
Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease.从过去中学习：阿尔茨海默病中针对淀粉样蛋白、tau 和神经炎症的临床试验综述。
Curr Alzheimer Res. 2020;17(2):112-125. doi: 10.2174/1567205017666200304085513.

引用本文的文献

1
Unnatural foldamers as inhibitors of Aβ aggregation stabilizing the Aβ helix.非天然折叠体作为β-淀粉样蛋白聚集的抑制剂，稳定β-淀粉样蛋白螺旋。
Chem Commun (Camb). 2025 Mar 19;61(24):4586-4594. doi: 10.1039/d4cc05280c.
2
Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment.用于阿尔茨海默病治疗的基于脂质纳米颗粒的药物递送策略。
J Nanobiotechnology. 2025 Feb 10;23(1):99. doi: 10.1186/s12951-025-03109-3.
3
Network pharmacology and experimental verification to investigate the mechanism of isoliquiritigenin for the treatment of Alzheimer's disease.

本文引用的文献

1
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.强效、选择性且口服生物可利用的γ-分泌酶抑制剂BMS-708163的发现与评价
ACS Med Chem Lett. 2010 Mar 22;1(3):120-4. doi: 10.1021/ml1000239. eCollection 2010 Jun 10.
2
Antiamyloid therapy for Alzheimer's disease--are we on the right road?用于治疗阿尔茨海默病的抗淀粉样蛋白疗法——我们走在正确的道路上吗？
N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.
3
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
网络药理学与实验验证相结合探究异甘草素治疗阿尔茨海默病的机制
Sci Rep. 2025 Feb 5;15(1):4379. doi: 10.1038/s41598-025-88542-y.
4
Calcium Signalling in Neurological Disorders, with Insights from Miniature Fluorescence Microscopy.基于微型荧光显微镜技术对神经疾病中钙信号传导的见解
Cells. 2024 Dec 25;14(1):4. doi: 10.3390/cells14010004.
5
Insights into the use of biomarkers in clinical trials in Alzheimer's disease.浅析生物标志物在阿尔茨海默病临床试验中的应用。
EBioMedicine. 2024 Oct;108:105322. doi: 10.1016/j.ebiom.2024.105322. Epub 2024 Oct 3.
6
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials.用于转译神经tau 病变疗法的框架：从药物发现到临床试验。
Alzheimers Dement. 2024 Nov;20(11):8129-8152. doi: 10.1002/alz.14250. Epub 2024 Sep 24.
7
Subjective cognitive and olfactory impairments predict different prospective dementia outcomes.主观认知和嗅觉障碍预示着不同的未来痴呆结局。
Chem Senses. 2024 Jan 1;49. doi: 10.1093/chemse/bjae033.
8
A Systematic Online Living Evidence Summary of experimental Alzheimer's disease research.实验性阿尔茨海默病研究的系统性在线活体证据总结。
J Neurosci Methods. 2024 Sep;409:110209. doi: 10.1016/j.jneumeth.2024.110209. Epub 2024 Jul 2.
9
Exploring the clinical transition of engineered exosomes designed for intracellular delivery of therapeutic proteins.探索设计用于细胞内递呈治疗性蛋白的工程化细胞外囊泡的临床转化。
Stem Cells Transl Med. 2024 Jul 15;13(7):637-647. doi: 10.1093/stcltm/szae027.
10
New precision medicine avenues to the prevention of Alzheimer's disease from insights into the structure and function of γ-secretases.从 γ-分泌酶的结构和功能角度探讨预防阿尔茨海默病的新精准医学途径。
EMBO J. 2024 Mar;43(6):887-903. doi: 10.1038/s44318-024-00057-w. Epub 2024 Feb 23.
两项评估 bapineuzumab 治疗轻度至中度阿尔茨海默病的 3 期临床试验。
N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.
4
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.用于轻中度阿尔茨海默病的 solanezumab 的 3 期临床试验。
N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889.
5
Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization.人阿尔茨海默病和主动淀粉样β42 免疫后的炎症成分。
Brain. 2013 Sep;136(Pt 9):2677-96. doi: 10.1093/brain/awt210. Epub 2013 Aug 13.
6
A phase 3 trial of semagacestat for treatment of Alzheimer's disease.一项用于治疗阿尔茨海默病的司美吉林的 3 期临床试验。
N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951.
7
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.淀粉样蛋白成像和 CSF 生物标志物可预测 7.5 年后的认知障碍。
Neurology. 2013 May 7;80(19):1784-91. doi: 10.1212/WNL.0b013e3182918ca6. Epub 2013 Apr 10.
8
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.巴喷丁结合阿尔茨海默病淀粉样β肽的 N 端以螺旋构象存在。
Sci Rep. 2013;3:1302. doi: 10.1038/srep01302.
9
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.静脉注射免疫球蛋白治疗轻中度阿尔茨海默病的 2 期随机、双盲、安慰剂对照、剂量探索试验。
Lancet Neurol. 2013 Mar;12(3):233-43. doi: 10.1016/S1474-4422(13)70014-0. Epub 2013 Jan 31.
10
A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.一种针对淀粉样斑块的抗体可清除阿尔茨海默病小鼠体内的现有β-淀粉样斑块。
Neuron. 2012 Dec 6;76(5):908-20. doi: 10.1016/j.neuron.2012.10.029.